Drizzle Health develops sample concentration technology using patented tunable polymers to improve the sensitivity of diagnostic tests across food safety, clinical diagnostics, and biosecurity. The company offers products such as MagnaSlide for microscopy and MagnaFlow for inline processing to capture and concentrate target pathogens without the need for overnight enrichment.
Subscribe to see Drizzle Health, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Drizzle Health, LLC is a diagnostics company headquartered in United States. Its most recent funding round raised $500,000 in November 2024. Xcout tracks 6 named people at Drizzle Health, LLC, including Digvijay Singh (President).
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $500,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Drizzle Health, LLC's closest competitors — see the full list of competitors and alternatives →
SnapDNA provides rapid molecular diagnostic systems for food safety testing to help food companies detect pathogens like Listeria, Salmonella, and E. coli in approximately one hour. Their self-contained, cloud-connected instruments enable on-site, quantitative analysis of live cells without requiring a laboratory or specialized technical skills.
MicroVizual Inc. develops a tape-based infrastructure platform that automates and digitizes histology workflows for research and clinical environments. The company's proprietary technology replaces traditional glass slides with continuous roll media to improve sample handling, throughput, and AI-readiness in pathology.
Immy Inc. develops, manufactures, and distributes diagnostic tests, reagents, and processing systems specializing in mycology. The company serves healthcare professionals, reference laboratories, and hospital settings by providing lateral flow assays, enzyme immunoassays, and PCR tests for the detection of fungal diseases.
GNA Biosolutions GmbH is a German biotechnology company developing rapid molecular-diagnostics systems, including instruments and consumables for automated nucleic-acid extraction and amplification. Its solutions are intended for applications such as clinical testing, research, and other settings requiring fast pathogen or genetic analysis.
Sansure Biotech Inc., founded in Changsha, China, in 2008, is dedicated to the global development and commercialization of advanced diagnostic and research products. The company offers a diverse range of solutions, including upstream nucleic acid extraction kits, real-time PCR systems for both clinical and investigative purposes, and fluorescence detection platforms. Their extensive product portfolio encompasses diagnostic assays for critical conditions like the novel coronavirus, viral hepatitis, and AIDS. Furthermore, they provide blood screening and general extraction kits, tests for cancer-related biomarkers, and solutions for respiratory, sexually transmitted, digestive tract, prenatal, postnatal, and genetic diseases. Sansure Biotech also supplies essential laboratory instrumentation and various consumables, primarily serving hospitals and scientific laboratories worldwide.
Adarza BioSystems, Inc. is a biotechnology company headquartered in St. Louis, Missouri, focused on label-free detection biosystems and life sciences solutions.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.